As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could ...

Parexel’s Stacy Hurt draws on her experience with chemotherapy and as a caregiver to spot patient burdens that AI-assisted ...

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the ...

Roche and Genentech’s multiple sclerosis drug Ocrevus launched like a firework in 2017, achieving blockbuster status within a year while making a mark on an already crowded market with a brand-new ...

However, despite this progress, the bioprocessing industry still struggles to use this data in a way that consistently ...

What if a cancer drug works, but not the way scientists thought it would? A recent study found evidence of just that in laboratory models of glioblastoma, involving the research compound QC6352 and a ...

Pharma has more drugs to test. But the system built to test them is under strain. The number of drugs in phase 2 and 3 has climbed about 9% year over year, according to a new analysis by Bain & ...

Turn Therapeutics CEO Bradley Burnam didn’t set out to recruit two U.S. regulatory big wigs for his biotech. But common scientific interests, professional connections and an interview on the CEO’s ...

The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...

Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...